Abdominal fat in HIV-associated lipodystrophy
A controlled trial found reduced visceral fat in adults with this diagnosis. It was not a study of general obesity treatment.
Read the publication
Physician-led care in the UAE
Peptide care · Pen
Tesamorelin Pen
Randomized trials show reductions in abdominal fat in adults with HIV-associated lipodystrophy, a specific medical condition.
- Discuss your health goals and suitability with a physician
- Your prescribed preparation is confirmed during care
- Clinical review and follow-up guide the next steps
- Format
- Pen
- Strength
- 10 mg/ml
- Size
- 3 ml
- Route
- Subcutaneous injection
Suitability reviewed by a UAE-licensed physician
Confirm the dispensing pharmacy and preparation before treatment
Completing an assessment does not guarantee a prescription
Formats reflect the supplied catalog, not a prescription or confirmation of availability. Health topics describe scientific interest, not approved indications. Read the specific studies and preparation limits.
The role of this peptide
Where Tesamorelin
has been studied.
The metabolic-health association has human clinical evidence, but the diagnosis is central. These findings do not establish general weight-loss treatment.
Liver fat in a specific population
A smaller trial found reduced liver fat in people with both HIV and fatty liver disease. That result cannot be extended to every metabolic concern.
Read the publicationSafety & suitability
Is Tesamorelin right for you?
The approved product label includes contraindications and monitoring related to pregnancy, malignancy, IGF-1 and glucose. Review the full label with a clinician.
FDA approval applies to EGRIFTA for excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for weight-loss management. This does not approve a DarDoc compounded preparation or establish UAE authorization.
DailyMed: EGRIFTA WR prescribing informationSuitability depends on the specific preparation, intended use and clinical assessment. Product authorization must be verified separately from facility licensing.
The evidence
Tesamorelin:
what has been studied.
Clinical trials found changes in visceral or liver fat in specific groups of people with HIV. Those results do not establish a general weight-loss treatment.
At six months, visceral fat decreased by 10.9% with tesamorelin versus 0.6% with placebo.
404 adults with HIV-associated abdominal fat · Subcutaneous
What remains uncertain
Read the studyThe population had a specific HIV-related condition. This is not evidence for general obesity treatment.
The study found a greater reduction in liver fat with tesamorelin over 12 months.
61 adults with HIV and fatty liver disease · Subcutaneous
What remains uncertain
Read the studyA small study in people with both HIV and fatty liver disease; not a general metabolic-health claim.
About this evidence review
The studies used subcutaneous tesamorelin, but a shared route does not establish equivalence between the studied medicine and a compounded pen or vial.
Reviewed September 15, 2026. Selected publications, not a systematic review. Findings do not establish product authorization.
Our review approachFor your consultation
Know what to ask.
Three questions to help you discuss Tesamorelin Pen. Your clinician decides which preparation, checks and follow-up are relevant.
01
The preparation
What exactly are we considering?
What is the exact ingredient, formulation and strength, and how would it be used?
02
Your assessment
What needs checking first?
How would IGF-1 and blood glucose or HbA1c be assessed and followed in my situation?
03
Your follow-up
How will we review the plan?
What would count as a meaningful benefit, when would we review it, and which side effects should I report?
These questions are not a dosing schedule or a required test panel. Your clinician individualizes the plan.
A considered approach
to peptide care.
A peptide name is only the beginning. The preparation, clinical need and available evidence all matter to the decision.
Dr. Sami Mohammed Yesuf, MD
Medical Director & Physician, DarDoc
Dr. Marwa Abuaita, MD
Physician, DarDoc
- 01
Start with the clinical question
Discuss the symptoms or diagnosis behind your interest in a peptide, alongside current medicines and previous treatment.
- 02
Review the exact preparation
Consider the evidence for its route and intended use, its regulatory status, and established treatment alternatives.
- 03
Make an informed decision
Discuss potential benefits, uncertainties and risks. A prescription is considered only when clinically appropriate and permitted.
- 04
Agree how to review progress
If treatment is prescribed, agree on monitoring, side effects to report and when to reassess the plan.
SCOPE credentials shown relate to obesity medicine, not peptide-specific certification. The treating physician is confirmed at booking.
A few things to know
Your questions,
answered.
How is Tesamorelin Pen considered in a consultation?
Your physician reviews your symptoms, history, current medicines and goals. The discussion should include the specific evidence, risks, alternatives and a follow-up plan before any treatment decision.
What should I know about the safety of Tesamorelin Pen?
The approved product label includes contraindications and monitoring related to pregnancy, malignancy, IGF-1 and glucose. Review the full label with a clinician.
Can I order without a consultation?
Prescription treatment is considered only after clinical assessment. Browsing a format does not select a dose, determine eligibility or guarantee a prescription.
Continue exploring
More in this area.
Explore other products discussed in these health topics, with the evidence for each.
DarDoc peptidesPen
Metabolism · Healthy aging
MOTS-C Pen
10 mg/ml · 3 ml
A mitochondrial peptide studied in exercise biology. Animal treatment findings and measurements of naturally occurring MOTS-C in people are different kinds of evidence.
Bring your questions
Make your next step
a conversation.
Want to understand where Tesamorelin Pen fits? Discuss the evidence, your health history and the options with DarDoc.